The UK biotech OMass Therapeutics Ltd has appointed Rosamond Deegan as its chief executive officer to manage its high-resolution mass spectrometry platform for drug discovery. Ms Deegan joined from Bicycle Therapeutics Ltd where she was chief business officer and director of the company’s US subsidiary. Prior to this, she was head of business development and operations at Trevena Inc, a developer of medicines for central nervous system disorders. Ms Deegan is a graduate of Cambridge University and received her MBA from the French business school INSEAD.
OMass announced the appointment on 8 May 2019.
Copyright 2019 Evernow Publishing